Results 101 to 110 of about 15,674 (165)

Immune-inflammation index as prognostic markers in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. [PDF]

Front Oncol
Qin Z, Liu R, Jing S, Guo C, Li W.
europepmc   +1 more source

The Tumor Immune Microenvironment in Endometrial Cancer: Composition, Molecular Subtypes, and Therapeutic Implications

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Endometrial cancer (EC), a major gynecologic malignancy and a representative “cold tumor”, exhibits a tumor immune microenvironment (TIME) influenced by a broad range of cellular and molecular elements, immunosuppressive signals, and pathways of immune evasion.
Jingxuan Ye, Yashi Shi, Alexander Mustea, Xiaodan Mao, Pengming Sun   +4 more
wiley   +1 more source

Impact of Obesity on Systemic Treatment Outcomes in Metastatic Urological Malignancies

Obesity Science &Practice, Volume 12, Issue 3, June 2026.
ABSTRACT Introduction Obesity increasingly influences treatment outcomes in urological malignancies (metastatic bladder cancer (BC), renal cell cancer (RCC), and prostate cancer (PC)). This study evaluated the impact of obesity on survival in patients with major metastatic urological cancers receiving systemic therapy.
A. Handke, M. Silberg, C. Orf, C. Loeffelholz, P. Bach, S. Berg, F. Roghmann, K. H. Tully   +7 more
wiley   +1 more source

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy

The Prostate, Volume 86, Issue 8, Page 882-890, June 2026.
ABSTRACT Background Radiographic progression (RP) without prostate‐specific antigen (PSA) elevation has emerged as a clinically important pattern in the androgen receptor pathway inhibitors (ARPI) era, but its prevalence and prognostic significance in real‐world metastatic hormone‐sensitive prostate cancer (mHSPC) cohorts remain unclear.
Takeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, Takuya Tsujino, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Fumihiko Urabe, Masanobu Saruta, Atsuhiko Yoshizawa, Shingo Toyoda, Saizo Fujimoto, Kyosuke Nishio, Moritoshi Sakamoto, Tatsuo Fukushima, Ko Nakamura, Kazuki Nishimura, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Ryoichi Maenosono, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Kazutoshi Fujita, Kazumasa Komura, Haruhito Azuma   +27 more
wiley   +1 more source

Development of Prostate Cancer Intramuscular Metastasis During 177 Lu-PSMA-617 Treatment. [PDF]

Clin Nucl Med
Xie VK, Jahromi AH.
europepmc   +1 more source

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, Volume 86, Issue 9, Page 1043-1052, June 15, 2026.
ABSTRACT Purpose Previous studies have demonstrated an association between PSMA‐PET SUVmax and poorer survival outcomes in patients with mCRPC. However, limited data are available in mHSPC. We aim to investigate the relationship between baseline PSMA‐PET SUVmax and rPFS in patients with mHSPC.
Cevat İlteriş Kıkılı, Caner Kapar, Feyyaz Hazar Yağmur, Esra Arslan, Bahadır Köylü, Fatih Kemik, Buğra Han Esen, Nazan Demir, İlkay Gültürk, Murat Polat, Fatih Selçukbiricik, Deniz Tural   +11 more
wiley   +1 more source

Extracellular vesicles as mediators of prostatic diseases: connecting function to diagnostic and therapeutic applications. [PDF]

Extracell Vesicles Circ Nucl Acids
Bishara J, Morakinyo M, Saini S.
europepmc   +1 more source

Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target

The Prostate, Volume 86, Issue 9, Page 1061-1068, June 15, 2026.
ABSTRACT Introduction The clinical relevance of HER2 expression profile in solid cancers has expanded with the evolving landscape of HER2 targeting agents. This systematic review and meta‐analysis aim to detail the prevalence of HER (over)expression in prostate cancer and identify patient/disease subgroups with enriched HER2 overexpression.
Jacky T. F. Luk, Alex H. Lin, Esther K. C. Cheung, Renald Meçani, Taulant Muka, Jana Nano, Joanna K. M. Ng, Matthew K. L. Chiu, Bryan C. W. Li, Rong Na, Joshua J. X. Li   +10 more
wiley   +1 more source

Comparative Analysis of ISM-1 and B7-H3 Expression in Castration-Resistant Prostate Adenocarcinoma: Associations with Tumor Aggressiveness and Resistance Dynamics. [PDF]

Medicina (Kaunas)
Kaya Ş, Öztürk A, Yüceer RO, Öztürk NB.   +3 more
europepmc   +1 more source

Mediation Analysis With Bayesian Nonlinear Joint Models: Evaluation of the Treatment Causal Pathways Between Tumor Growth Kinetics and Overall Survival

Statistics in Medicine, Volume 45, Issue 13-14, June 2026.
ABSTRACT Understanding the mechanisms through which anti‐cancer treatments influence survival is central to improving drug development and evaluation. In this work, we develop a Bayesian joint modeling framework for mediation analysis to quantify the extent to which tumor size dynamics mediate the effect of treatment on overall survival (OS). Our model
Georgios Kazantzidis, Francois Mercier, Virginie Rondeau   +2 more
wiley   +1 more source